Edwards Lifesciences (EW) Tax Provisions (2009 - 2026)

Edwards Lifesciences has reported Tax Provisions for 18 years, with the latest figure at $278.4 million in Q2 2026.

• On a quarterly basis, Tax Provisions rose 332.97% year-over-year to $278.4 million in Q2 2026; TTM through Jun 2026 was $439.0 million, a 99.18% increase from a year earlier, with the FY2025 full-year figure at $216.9 million, up 42.6% from the prior year.
• Tax Provisions was $278.4 million for Q2 2026 at Edwards Lifesciences, up from $78.3 million in the prior quarter.
• The five-year high for Tax Provisions was $278.4 million in Q2 2026, with the low at $10.9 million in Q4 2022.
• Average Tax Provisions over 5 years is $60.4 million, with a median of $54.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Tax Provisions plunged 73.41% in 2022, then surged 332.97% in 2026.
• Over 5 years, Tax Provisions stood at $10.9 million in 2022, then surged by 212.84% to $34.1 million in 2023, then jumped by 32.26% to $45.1 million in 2024, then plunged by 41.91% to $26.2 million in 2025, then surged by 962.6% to $278.4 million in 2026.
• The last three Tax Provisions figures came in at $278.4 million (Q2 2026), $78.3 million (Q1 2026), and $26.2 million (Q4 2025), per Business Quant data.